title: The validity of neuropathy and neuropathic pain measures in patients with cancer receiving taxanes and platinums.
abstract: OBJECTIVE
  To assess the validity of neuropathy and neuropathic pain-measurement approaches.
  
  
  METHODS
  Cross-sectional measurement study.
  
  
  METHODS
  Two comprehensive cancer centers in the northeastern United States.
  
  
  METHODS
  117 patients with cancer in an outpatient setting.
  
  
  METHODS
  Participants were assessed using the five-component Total Neuropathy Score-reduced (TNSr), the TNSr short form (TNSr-SF), individual TNSr items, the Neuropathic Pain Scale for chemotherapy-induced neuropathy (NPS-CIN), and the National Cancer Institute's Common Toxicity Criteria™, version 3.0 (NCI-CTC).
  
  
  METHODS
  Neuropathy and pain measure scores, cumulative and per M2 chemotherapy dosage, comorbid risk factors, drug class, and the number of neurotoxic drugs received.
  
  
  RESULTS
  TNSr, TNSr-SF, and tendon reflex scores were greater in patients receiving higher cumulative (z range = -2.2 to -3.6; p range = 0.01 to < 0.001) and per M2 (z range = -1.8 to -2.4; p range = 0.04 to < 0.001) chemotherapy doses. Scores from most neuropathy and pain measures were higher in patients with comorbid illnesses (z range = -1.79 to -3.51; p range = 0.03 to < 0.001). Sensory NCI-CTC scores were higher in patients receiving higher cumulative chemotherapy dosage (z = -2.1; p = 0.02). Only the sensory NCI-CTC correlated with other measures (r range = 0.22-0.63; p range = 0.05 to < 0.001).
  
  
  CONCLUSIONS
  Findings support the validity of the TNSr, TNSr-SF, tendon reflex item, NPS-CIN, and NCI-CTC sensory grading scale when measuring taxane and platinum-induced neuropathy. However, additional validity testing is warranted.
  
  
  CONCLUSIONS
  Comprehensive neuropathy and pain measures mainly used by researchers and neurologists were simplified to more clinically useful tools for use by nurses when monitoring chemotherapy-induced peripheral neuropathy.
authors.affiliation: School of Nursing, University of Michigan, Ann Arbor, USA. Ellenls@umich.edu
authors.forename: Ellen M
authors.initials: EM
authors.lastname: Lavoie Smith
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Cohen
authors.forename: Marjorie A
authors.initials: MA
authors.lastname: Pett
authors.forename: Susan L
authors.initials: SL
authors.lastname: Beck
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D015897:Comorbidity; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000451:nursing; D009437:Neuralgia / Q000139:chemically induced* / Q000453:epidemiology / Q000451:nursing*; D009730:Nursing Assessment / Q000592:standards; D009859:Oncology Nursing / Q000379:methods; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects*; D010147:Pain Measurement / Q000592:standards*; D015203:Reproducibility of Results; D012307:Risk Factors; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D043823:Taxoids; D000077150:Oxaliplatin; D000077143:Docetaxel; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin